Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.72 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.66 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879886 | 0.98 | HRH3 (0.68) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| SCHEMBL2327735 | 0.86 | MBTD1 (0.63) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| SCHEMBL4277270 | 0.85 | HRH3 (1.00) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| SCHEMBL2249251 | 0.83 | HRH3 (0.78) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| Hydrochloric Acid SCHEMBL7468055 | 0.83 | HRH3 (0.95) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| SCHEMBL11201497 | 0.82 | HRH3 (0.94) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| SCHEMBL13958981 | 0.82 | L3MBTL1 (0.96) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| SCHEMBL13958507 | 0.82 | L3MBTL1 (0.96) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| SCHEMBL13959546 | 0.82 | L3MBTL1 (0.96) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 | |
| Hydrochloric Acid SCHEMBL31103424 | 0.82 | HRH3 (0.75) | HRH3MBTD1L3MBTL3L3MBTL1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| WO-2013171281-A1 | HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS | VIVALIS (FR) | 2013-11-21 | — | — | WO | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| EP-2464632-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| CN-101443320-A | Benzothiazole derivatives as beta 2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-05-27 | — | — | CN | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1996566-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106016-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | PSEN1, PRNP, PSEN2 | HRH3 662/4885MBTD1 1704/4885L3MBTL3 1705/4885 |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | HRH3 41/4885MBTD1 686/4885L3MBTL3 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.